Study ID: CTSU R0815

Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy with or without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate Cancer


The purpose of this study is to compare the effects of dose-escalated radiation therapy with or without hormone therapy on prostate cancer participants. Participants in this study have been diagnosed with intermediate-risk prostate cancer. Prior studies have suggested possible advantages to the administration of hormonal therapy with radiation. However, those studies were performed with radiation techniques that do not match those commonly used in clinical practice today. Therefore, this study will be testing to see if similar benefits for hormonal therapy are seen when sued with current radiation therapy techniques. This study is testing whether the side effects of hormonal therapy are outweighed by an advantage in prostate cancer cure rates for patients receiving that treatment.

Bemidji Clinic, Bismarck Region, Fargo Region
Principal Investigator:
Preston Steen, MD,Preston Steen, MD,Preston Steen, MD
Phase III


Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.

Back to Clinical Trials list